Caroline Even

Department Of Head And Neck Surgery
Villejuif, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 130 publications

Sinonasal squamous cell carcinoma: REFCOR guidelines for diagnosis, treatment and follow-up.

Sinonasal squamous cell carcinoma: REFCOR guidelines for diagnosis, treatment and follow-up.

Journal: European annals of otorhinolaryngology, head and neck diseases
Published: July 06, 2026

REFCOR guidelines for sinonasal adenocarcinoma.

REFCOR guidelines for sinonasal adenocarcinoma.

Journal: European annals of otorhinolaryngology, head and neck diseases
Published: May 09, 2026

Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.

Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.

Journal: European annals of otorhinolaryngology, head and neck diseases
Published: May 09, 2026

Author Reply.

Author Reply.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: May 06, 2026

Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study).

Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study).

Journal: Oral oncology
Published: April 12, 2026

HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.

HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 18, 2026

Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 12, 2026

REFCOR guidelines for sinus and nasal cavity cancer.

REFCOR guidelines for sinus and nasal cavity cancer.

Journal: European annals of otorhinolaryngology, head and neck diseases
Published: February 20, 2026

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Journal: Oral oncology
Published: February 20, 2026

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

Journal: Molecular cancer
Published: February 15, 2026

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

Journal: European journal of cancer (Oxford, England : 1990)
Published: February 10, 2026

Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.

Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 22, 2026
Showing 1-12 of 130

Last Updated: 09/26/2026